RecruitingNot Applicable

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

United States70 participantsStarted 2025-12-19

Plain-language summary

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies * Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment * If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening Exclusion Criteria: * Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk * Is MGFA (Myasthenia Gravis Foundation of America) Class V

What they're measuring

To determine the safety and tolerability of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypes

Timeframe: Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)

Trial details

NCT IDNCT07294170

Sponsorargenx

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-03-07

Contact for this trial

Sabine Coppieters, MD

857-350-4834 clinicaltrials@argenx.com

View on ClinicalTrials.gov More Myasthenia Gravis trials